Takeda Research Investment’s Graeme Martin on Corporate Venture Capital’s New Role In Developing Next-Generation Biologics: An Interview With PharmAsia News (Part 1 of 2)

Attend any industry conference these days, and a general theme will appear that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage research, could impact long-term future development of emerging biotechnologies. Graeme Martin, president of Takeda's corporate venture arm Takeda Research Investment, talks with PharmAsia News about the changing scope of corporate venture capital in this atmosphere as well as the role of CVC in helping inform companies' development strategies.